These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25135032)

  • 1. Fentanyl sublingual spray for breakthrough pain in cancer patients.
    Zeppetella G
    Pain Ther; 2013 Jun; 2(1):1-9. PubMed ID: 25135032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough pain in cancer patients.
    Zeppetella G
    Clin Oncol (R Coll Radiol); 2011 Aug; 23(6):393-8. PubMed ID: 21227666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for breakthrough cancer pain.
    Mercadante S
    Drugs; 2012 Jan; 72(2):181-90. PubMed ID: 22233484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose fentanyl sublingual spray for breakthrough cancer pain.
    Taylor DR
    Clin Pharmacol; 2013; 5():131-41. PubMed ID: 23901300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management.
    Zeppetella G
    Eur J Cancer Care (Engl); 2009 Jul; 18(4):331-7. PubMed ID: 19473378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl for breakthrough cancer pain: where are we?
    Meriggi F; Zaniboni A
    Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
    Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
    Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain.
    Prommer E; Ficek B
    Patient Prefer Adherence; 2012; 6():465-75. PubMed ID: 22791984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
    Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
    Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
    Mercadante S
    Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.